

IDENTIFYING NEO-EPITOPES WITH NEOEPIOTOPE DIRECT™

WHY PREDICT WHEN YOU CAN OBSERVE?

With Caprion-HistoGeneX's NEOEPIOTOPE DIRECT™, neo-epitope identification is achieved directly from tissue not from prediction algorithms. Our solution allows for confident identification, qualification, and characterization of naturally presented tumor antigens relative to adjacent normal tissue.

Antigens are presented, not predicted.

A FASTER, EFFICIENT & MORE RELIABLE PATHWAY TO DISCOVERY


The race to identify neo-epitopes is crucial for immune system research and critical in drug and vaccine development. Universally, innovative pharmaceutical and biotech companies recognize the power of mass spectrometry to identify peptide sequences involved with T-cell responses. At the same time, many rely on voluminous immunoinformatic prediction databases that often, at the end of a long discovery process, provide predictive results as opposed to observed.

NEOEPIOTOPE DIRECT™

ONE-OF-A-KIND APPROACH TO GENERATE FEWER, BUT BETTER CHARACTERIZED TARGETS

THE POWER OF OBSERVATION

DISCOVERY




Mass Spectrometry

Primary tissue/*in vitro* models:
Identify peptides present on
the surface of cells and visible
to T cells



PRIORITIZATION




AntigenAtlas™

Proprietary healthy tissue
database: Qualify and
prioritize candidate targets



CHARACTERIZATION




ELISpot

Comprehensive assessment
of T-cell response: Sensitive
and rapid confirmation of
antigen-specific response



CONFIDENCE



High quality immuno-oncology
targets identified for:
vaccines, CAR-T and Ab

NEOEPI TOPE DIRECT™

THE OPTIMAL WORKFLOW THAT SHORTENS YOUR DEVELOPMENT CYCLE

Based on years of mass spectrometry expertise, NEOEPI TOPE DIRECT™ is a rigorous and reproducible solution that offers a more reliable pathway to your immuno-oncology discovery.

Mass Spectrometry (LC-MS/MS)

Accurate and Reliable

Increased sensitivity and confident peptide identification as a result of high-resolution MS/MS data.

AntigenAtlas™

Comprehensive and Up-to-date

Our proprietary healthy tissue database, developed by immunology scientists and bioinformatics experts, allows better interpretation and prioritization of the data.

ELISpot

Quick and Efficient

Characterize immune reactivity to candidate targets in autologous or heterologous systems.

ADVANTAGES

- ▼ Directly identifies naturally presented tumor antigens relative to adjacent normal tissue
- ▼ Focuses on naturally processed peptides that are presented by MHC complexes *in vivo*
- ▼ Reduces reliance on epitope modeling
- ▼ Better characterized candidates for follow-up
- ▼ Increased coverage of different HLA types

WHAT OUR CLIENTS SAY

"A robust platform that can be depended on to consistently provide high quality data run after run."

"Peptides identified needed to meet specific length and predict affinity."

Meeting these criteria indicated that the peptides identified were high quality, and could be confidently used in further analysis."

ABOUT CAPRION - HISTOGENEX

Leading provider of immune monitoring, genomics, histopathology, and biomarker development services to the biopharmaceutical industry with laboratory facilities located globally. Leveraging its integrated platforms, Caprion-HistoGeneX supports the entire drug development cycle, from discovery to clinical trials.

FOR MORE INFORMATION

CAPRION.COM

info@caprion.com

HEADQUARTERS (CAPRION BIOSCIENCES INC.)

141 President Kennedy Ave., Suite SB-5650

Montreal, Quebec, CANADA H2X 1Y4

Toll Free: +1 877 776 3443

Phone: +1 514 360 3600

LABORATORY LOCATIONS:

NORTH AMERICA: Montreal (Canada) | Fremont (USA) | Carlsbad (USA) | Naperville (USA)

EUROPE: Gosselies (Belgium) | Guildford (UK) | Antwerp (Belgium)

ASIA-PACIFIC: Sydney (Australia) | Jining (China)